Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | TG4050 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TG4050 | TG-4050|TG 4050 | TG4050 is a vaccine consisting of modified Vaccinia virus Ankara (MVA) with tumor-specific neoantigens that stimulate the immune system (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04183166 | Phase I | TG4050 | A Clinical Trial Evaluating TG4050 in Head and Neck Cancer | Recruiting | USA | FRA | 1 |
NCT03839524 | Phase I | TG4050 | A Trial Evaluating TG4050 in Ovarian Carcinoma. | Recruiting | USA | FRA | 0 |